← Back to patent-cliff list
CAS 100-66-3
anisole
Codes: EMPA-002, Lopix-021
Application context (from source-drug indications)
Chronic renal impairmentEmpagliflozinHeart failureEmpagliflozinType 2 diabetesEmpagliflozinPruritusMaralixibat Chloride进行性家族性肝内胆汁淤积症Maralixibat ChlorideAlagille综合征Maralixibat Chloride胆汁淤积Maralixibat ChlorideLiver diseaseMaralixibat Chloride肝内胆汁淤积Maralixibat Chloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Empagliflozin | Tier A — Act now | 2028 |
| Maralixibat Chloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
5-bromo-2-chlorobenzoic acid→anisole→(5-bromo-2-chlorophenyl)(4-methoxyphenyl)methanone→4-bromo-1-chloro-2-(4-methoxybenzyl)benzene→4-(5-bromo-2-chlorobenzyl)phenol→(4-(5-bromo-2-chlorobenzyl)phenoxy)(tert-butyl)dimethylsilane→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→(2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol→(R)-tetrahydrofuran-3-yl 4-methylbenzenesulfonate→(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-one
1-Benzothiepin-4-ol, 3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-5-(4-methoxyphenyl)-, 1,1-dioxide, (4R,5R)-rel→1-Benzothiepin-4-ol, 3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-5-(4-hydroxyphenyl)-, 1,1-dioxide, (4R,5R)→1,4-bis(chloromethyl)benzene→1-Benzothiepin-4-ol, 3,3-dibutyl-5-[4-[[4-(chloromethyl)phenyl]methoxy]phenyl]-7-(dimethylamino)-2,3,4,5-tetrahydro-, 1,1-dioxide, (4R,5R)→5-chloro-2-nitrobenzoic acid→anisole→(2-chloro-5-nitrophenyl)(4-methoxyphenyl)methanone→1-chloro-2-(4-methoxybenzyl)-4-nitrobenzene→2-butyl-2-((2-(4-methoxybenzyl)-4-nitrophenylthio)methyl)hexanal→2-butyl-2-((2-(4-methoxybenzyl)-4-nitrophenylsulfonyl)methyl)hexanal→2-((4-amino-2-(4-methoxybenzyl)phenylsulfonyl)methyl)-2-butylhexanal→benzyl 4-(2-butyl-2-formylhexylsulfonyl)-3-(4-methoxybenzyl)phenylcarbamate→Lopix-028→Lopix-029
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | (5-Bromo-2-chlorophenyl)(4-fluorophenyl)methanone Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | (5-Bromo-2-chlorophenyl)[4-[[(3S)-tetrahydro-3-furanylloxy]phenyllmethanone Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | (S)-3-[4-[(2-Chloro-5-iodophenyl)methyl]phenoxy]tetrahydrofuran Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | (S)-3-[4-[(5-Bromo-2-chlorophenyl)methyl]phenoxy]tetrahydrofuran Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl] -D-glucitol tetraacetate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | (S)-(+)-3-Hydroxytetrahydrofuran Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 4-((5-Bromo-2-chlorophenyl)methyl)phenol Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.